Zai Lab Limited (ZLAB)
Zai Lab Limited (ZLAB) Stock Price, Analysis & Data
| Bid | 13.12 |
| Market Cap | 2.91B |
| Revenue (ttm) | 449.61M |
| Net Income (ttm) | -188.21M |
| Beta | 0.78 |
| EPS (ttm) | -1.7 |
| PE Ratio (ttm) | n/a |
| Forward PE | -12.57 |
| P/B (ttm) | 4.34 |
| P/S (ttm) | 6.47 |
| Earnings Date | Nov 5, 2026 |
| Ask | 23.88 |
| Volume | 1,234,060 |
| Avg. Volume (20D) | 963,659 |
| Open | 25.44 |
| Previous Close | 26.03 |
| Day's Range | 25.33 - 26.26 |
| 52-Week Range | 15.96 - 36.77 |
| Analyst | Strong Buy |
| Price Target | 28.27 (9.15%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ZLAB
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammat...
Financial Performance
In 2025, Zai Lab's revenue was 460.16M, an increase of 15.33% compared to the previous year's 398.99M. Earnings were -175.54M, a decrease of -31.73%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for ZLAB stock is "Strong Buy". The 12-month stock price forecast is 28.27, which is upside of 9.15% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
